Launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials - Glenmark Pharmaceuticals Ltd

Code BSE: 532296 NSE: $GLENMARK Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.”